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The EP2 receptor has emerged as a therapeutic target with exacerbating role in disease pathology for a variety of
peripheral and central nervous system disorders. We and others have recently demonstrated beneficial effects of
EP2 antagonists in preclinical models of neuroinflammation and peripheral inflammation. However, it was
earlier reported that mice with global EP2 knockout (KO) display adverse phenotypes on fertility and blood
pressure. Other studies indicated that EP2 activation with an agonist has a beneficial effect of healing fractured
bone in animal models. These results impeded the development of EP2 antagonists, and EP2 antagonism as
therapeutic strategy. To determine whether treatment with EP2 antagonist mimics the adverse phenotypes of the
EP2 global KO mouse, we tested two EP2 antagonists TG11–77. HCl and TG6–10–1 in mice and rats while they
are on normal or high-salt diet, and by two different administration protocols (acute and chronic). There were no
adverse effects of the antagonists on systolic and diastolic blood pressure, heart rate, respiratory function in mice
and rats regardless of rodents being on a regular or high salt diet. Furthermore, chronic exposure to TG11–77.
HCl produced no adverse effects on blood cell counts, bone-volume and bone-mineral density in mice. Our
findings argue against adverse effects on cardiovascular and respiratory systems, blood counts and bone structure
in healthy rodents from the use of small molecule reversible antagonists for EP2, in contrast to the genetic
ablation model. This study paves the way for advancing therapeutic applications of EP2 antagonists against
diseases involving EP2 dysfunction.

Abbreviations: ACN, acetonitrile; AD, Alzheimer’s disease; AERD, aspirin-exacerbated respiratory disease; ALS, amyotrophic lateral sclerosis; ANOVA, Analysis of
variance; Aβ, amyloid-beta; BL, baseline; BPM, beats per minute; BT, body temperature; BW, body weight; CBC, complete blood count; COX-1, cyclooxygenase 1;
COX-2, cyclooxygenase 2; DBP, diastolic blood pressure; DI, deionized; DMSO, dimethyl sulfoxide; EDTA, ethylenediaminetetraacetic acid; PGE2, prostaglandin-E2;
EP1, prostaglandin-E2 receptor-1; EP2, prostaglandin-E2 receptor-2; EP3, prostaglandin-E2 receptor-3; EP4, prostaglandin-E2 receptor-4; HCT, hematocrit; HGB,
hemoglobin; HR, heart rate; HSD, high salt diet; H&E, hematoxylin and eosin; IL-6, interleukin 6; IP, intraperitoneal; JAK, janus kinase; LC-MS/MS, liquid chro
matography with tandem mass spectrometry; LLOQ, lower limit of quantification; MAP, mean arterial pressure; MV, minute volume; µCT, microcomputed to
mography; NaCl, sodium chloride; PBS, phosphate buffered saline; PD, Parkinson’s disease; PDWc, platelet distribution width; PEG, polyethylene glycol; PI, post
injection; PT, post treatment; PP, pulse pressure; p38 MAPK, p38 mitogen-activated protein kinase; RBC, red blood cells; RF, respiratory frequency; SBP, systolic
blood pressure; SD, Sprague Dawley; STAT3, signal transducer and activator of transcription 3; TG6–10–1, potent and selective EP2 receptor antagonist; TG11–77.
HCl, potent & selective EP2 receptor antagonist; TV, tidal volume; WBC, white blood cell; VOI, volume-of-interest; Veh, vehicle.
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1. Introduction

2. Materials and methods

Inflammation is the natural response of the immune system chal
lenged with either sudden or chronic insult. Inflammation is associated
with neurodegenerative diseases, cancer, diabetes, and cardiovascular
diseases [1,2]. Signaling pathways involved in inflammation include
p38 MAPK, IL-6/JAK/STAT3, PI3K, Hippo [3], and COX-2 [4]. Activa
tion of these inflammatory pathways is an essential step in restoring
normalcy and maintaining homeostasis. However, prolonged activation
leads to secondary damage in nearby cells and tissues. To prevent
deleterious effects of prolonged inflammation, targeting the pathways
with small molecule drugs could be an effective strategy. Prosta
glandin-E2 (PGE2), a lipid mediator that is ubiquitously present in tis
sues, is synthesized from arachidonic acid by cyclooxygenase-1 (COX-1)
or cyclooxygenase-2 (COX-2) as the rate limiting enzymes [2]. PGE2
exerts its physiological and pathological effects via four G-protein
coupled receptors (EP1, EP2, EP3, and EP4) [2,5]. PGE2 signaling via
EP2 is associated with increased inflammation in animal models of
status epilepticus [6-9], Alzheimer’s disease [10-12], Parkinson’s dis
ease [13], amyotrophic lateral sclerosis (ALS) [14], colitis [15], arthritis
[16], skin inflammation [17], endometriosis [18], sepsis [19] cancer
and tumor progression [20-25]. Moreover, in cell culture and mouse
models lacking EP2, activation of innate immunity is accompanied by
reduced cerebral oxidative damage [26], enhanced amyloid-β (Aβ)
phagocytosis [27], reduced neurotoxicity by Aβ-peptide [27,28], and
reduced Aβ-peptide accumulation [29]. Based on these observations,
inhibiting EP2 receptor pharmacologically could be an effective thera
peutic strategy for reducing inflammation in a variety of diseases [1].
While studies listed above encourage the development and clinical
advancement of EP2 antagonists for therapeutic applications, two
studies published in 1999 raised serious questions about the viability of
this target. Namely, one report showed that global EP2 KO in mice
causes reduced reproduction rate and significant elevation in blood
pressure with high salt diet compared to mice on regular diet [30].
Similarly, a study by Kennedy et al., showed that EP2 deletion in mice
results in salt-sensitive hypertension [31]. Subsequently, two other
studies using a selective EP2 agonist reported that activation of EP2
promotes healing of fractured bone in a canine model [32] and prevents
the degeneration of articular cartilage during the early stage of osteo
arthritis in rabbits [33], suggesting EP2 activation has beneficial roles in
bone repair and healing.
Furthermore, evidence suggests that EP2 receptor function is asso
ciated with protective effects against fibroproliferative lung disease,
aspirin-exacerbated respiratory disease (AERD), rhinitis and asthma
[34-38]. However, it was not clear whether EP2 has any role in normal
lung function, and if using an EP2 antagonist could lead to any adverse
effects on respiratory function.
To promote EP2 antagonists for preclinical and clinical use for any
disease indication, we must determine whether the adverse effects seen
in EP2 KO animals are replicated by the antagonists in healthy animals.
EP2 KO mice developed high systolic blood pressure only when they
were fed high-salt diet, but not normal diet [30,31]. Therefore, the
overall goal of this study was to test whether two EP2 selective antag
onists, TG6–10–1 and TG11–77. HCl, by acute and chronic administra
tion, have any adverse effects on cardiovascular function, respiratory
function, bone morphology and cellular composition of blood in normal,
non-disease mouse and rat models with or without high salt diet (HSD).
We used two structurally different EP2 antagonists with different
pharmacological profile; both mice and rats; two dosing protocols acute
vs chronic. Gratifyingly, the results presented in this study reveal no
adverse effects, and we conclude that the adverse effects observed in EP2
KO animals are not present with pharmacological EP2 antagonism.

2.1. Materials
EP2 antagonists TG11–77. HCl and TG6–10–1 (chemical structures
in supplementary Table S1) were synthesized and purified in our labo
ratory [6,39]. Pilocarpine was purchased from Sigma-Aldrich, prepared
in saline and injected at dose of 12 mg/kg to induce changes in heart rate
and blood pressure. Regular diet, containing 0.3% NaCl, was provided
by Emory University DAR, for high salt diet the Teklad diet containing
3.15% NaCl was used.
2.2. Animals
All animal procedures were approved by the Emory University Ani
mal Care and Use Committee and conformed to the guidelines of the
National Institutes of Health. Animals, C57Bl/6 mice (8–16 weeks old)
and SD rats (14–16 weeks old) used in this study were purchased from
Charles River Laboratories. Multiple cohorts of animals were used in this
study as shown in Table 1.
2.3. EP2 antagonist doses tested
We have shown that EP2 antagonist TG6–10–1 is anti-inflammatory,
neuroprotective and prevents cognitive deterioration in rats after status
epilepticus at a dose of 10 mg/kg via intraperitoneal injection [8,9],
therefore to assess the safety of this EP2 antagonist we selected 50
mg/kg (5-fold more than efficacious dose). Moreover, we have also
shown that EP2 antagonist TG11–77. HCl.2H2O is anti-inflammatory in
a mouse model of status epilepticus at 10 (free base 8.4) mg/kg I.P., and
can be administered orally by supplanting in drinking water, therefore
we used a projected oral dose of 100 (free base 84) mg/kg (>5-fold more
than efficacious dose) in this study. We used pilocarpine (a muscarinic
receptor agonist) at 12 mg/kg in the blood pressure and heart rate assays
to verify the sensitivity of the instrument.
2.4. EP2 antagonist administration in mice and rats
TG11–77. HCl was dissolved in water at pH 2.8–3.5 at concentration
of either 0.5 or 1.5 mg/ml with an aim to achieve a dosage of either 100
or 300 (free base 84 or 252) mg/kg/day respectively. Either water or
water containing TG11–77. HCl was provided to cages containing 3 mice
each for drinking. Consumption in ml was measured once a week and the
average amount of TG11–77. HCl utilized for each mouse was calculated
as mg/kg/day. The actual drug dose delivered was determined taking
into account the 92.5% recovery from the drinking water on 7th day at
room temperature, measured by HPLC. The resulting doses of drug are
shown in supplementary Table S1 and mentioned in the results section
for individual experiments. EP2 antagonist TG6–10–1 (a free base) has
low aqueous solubility so was dissolved in vehicle and administered via
intraperitoneal (IP) injection (see details below).
The antagonist TG6–10–1 (EP2 KB = 17.8 nM, > 10-fold selective
against other prostanoid receptors) has low water solubility (<25 µM)
with plasma half-life 1.7 h and brain-to-plasma ratio 1.7 after IP
administration [40], whereas TG11–77. HCl (EP2 KB = 9.7 nM, >
300-fold selective against other prostanoid receptors) has plasma
half-life of 2.4 hrs. brain-to-plasma ratio 0.4 by oral delivery, and high
water solubility (2.52 mM), which facilitate chronic dosing in drinking
water at the strength of 0.5 mg/ml [39]. These parameters guided us to
administer TG6–10–1 acutely by IP-injection and TG11–77. HCl by oral
dosing via drinking water. Moreover, the choice of the rodent is based on
the technical considerations and test compound requirement for the
planned experiments. For example, we preferred mice over rats for
chronic dosing of antagonist due to limited amount of compound needed
to treat the animals for nearly 2 months (Fig. 1A).
2
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Table 1
Animals, group numbers and dosing protocols used in experiments reported in this study.
Study
(Cohort)

species

Animals size/
group

No. groups

Gender
(approx. 1:1)

Dosing
protocol

Measurement

Technique used

1

Mice

N = 12

BP and HR

Tail-cuff method

Rats

N = 12

males &
females
males

Chronic

2

acute

BP and HR

Radiotelemetry

3

Rats

N=8

males

acute

Respiratory function

Plethysmography

4

Mice

N = 12

males

chronic

5

Mice

N = 28

chronic

Weights of vital organs and
Rotarod
CBC

Mice

N = 15

males &
females
males &
females

Organ and brain toxicity and
muscle weakness
Immune cell regulation

6

2 (vehicle and one dose
antagonist)
2 (vehicle and one dose
antagonist)
4 (vehicle, 5, 20 and 50 mg/
kg antagonist)
2 (vehicle and one dose
antagonist)
2 (vehicle and one dose
antagonist)
2 (vehicle and one dose
antagonist)

chronic

Bone phenotyping

µCT and histology

Fig. 1. EP2 antagonist TG11–77.HCl (57 mg/
kg/day for 5 weeks), treatment had no signifi
cant effect on mice body weight (BW), systolic
blood pressure (SBP) and heart rate (HR). (A)
Experimental paradigm for treatment of mice
with EP2 antagonist, TG11–77.HCl to study its
effect on blood pressure (BP), heart rate (HR)
and body weight, and test the effect of
TG11–77.HCl in comparison to control com
pound pilocarpine on BP and HR. (B) Change in
body weight (BW) (%) in mice treated with
either vehicle (water at pH 3.5) or TG11–77.
HCl. Compared to vehicle, mice treated with
TG11–77.HCl showed lower % increase in body
weight over the course of 5 weeks of treatment
10.7 vs 7.64 that was not statistically significant
(p = 0.11, unpaired t-test).(C) Effect of vehicle
vs TG11–77.HCl on change in body weight (%)
in male and female mice; the difference in
weight gain observed in female mice (vehicle vs
TG11–77.HCl) was compared to male mice. In
female mice, the % weight increase in vehicle
vs TG11–77.HCl treated mice was 9.83% vs
6.15% (p = 0.054, paired t-test), whereas in
male mice vehicle treated animal showed an
increase of 11.6% vs 9.13% in TG 11–77 treated
mice (p = 0.73, paired t-test). (D) Weekly
change in body weight (%) in mice treated with
vehicle vs TG11–77.HCl over the period of 5
weeks. Mice treated with TG11–77.HCl showed
marginal decrease in weight over the first week
of treatment, but it recovered in weeks 2
through 5, with weight gain similar to vehicle
treated mice. (E) Effect of vehicle vs TG11–77.
HCl on the BP of mice over the course of 5
weeks of treatment. TG11–77.HCl treatment
did not have any significant effect on BP
compared to vehicle treated mice over the
course of 5 weeks of treatment (104 mmHg vs
108 mmHg,
vehicle
vs
TG11–77.HCl,
p = 0.232, unpaired t-test). (F) Effect of vehicle
vs TG11–77.HCl on the HR of mice over the
course of 5 weeks of treatment. TG11–77.HCl
treatment had no significant effect on HR
compared to vehicle treated mice over the
course of 5 weeks of treatment (718 BPM vs 725
BPM, vehicle vs TG11–77.HCl, p = 0.564, un
paired t-test). p value of < 0.05 was considered
significant. The data are presented as mean
± SD.
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2.5. Experimental paradigm for chronic treatment of mice with EP2
antagonist

study days 7, 10, 11, 18, and 21. The same 12 animals from each group
were dosed on study days 7 (normal salt diet) and 18 (high salt diet) with
TG6–10–1 and on study days 10 and 21 with pilocarpine. The 24-hour
analysis period was divided into three different phases, analysis phase
1 (0–2 h after drug injection), analysis phase 2 (2–14 h) and analysis
phase 3 (14–24 h). Data are reported from analysis phase 1 as the
measured parameters returned to basal levels by 2 h. On all other days,
telemetry data were collected for 5 min every 60 min through the dosing
period. Clinical observations were collected once daily beginning with
administration of the regular diet (study day 0). Physical examination
(piloerection, appearance, scabbing, presence of any anomalies on nose
or neck, hair loss) were performed once weekly, and individual body
weights were collected on each day of dosing (prior to dosing) and once
weekly.
Statistical analysis: Analysis was performed for a period of 2 h post
injection (PI) and was compared to baseline (BL) values for the corre
sponding time point before injection. For BL, data was averaged for the
first 2 h and for PI data from every 30 min was used. 3-way ANOVA
(time, diet, and treatment) with Tukey’s multiple comparison test was
used to analyze the data. GraphPad Prism was used for analysis.

A total of 24 mice (cohort 1) were used in this study, n = 12 (6 males
and 6 females) in vehicle group and EP2 antagonist TG11–77. HCl
group. On day 0 (D0), after measuring body weight (BW), blood pressure
(BP) and heart rate (HR) using a tail-cuff method, mice were randomized
and separated in cages containing either vehicle (water at pH 3.5) or
TG11–77. HCl (0.5 mg/ml) resulting in a measured average consump
tion of 57 mg/kg/day free base (see supplementary Table S1). This dose
is 7–14-fold higher than the dose that achieves anti-inflammatory effi
cacy in an acute brain injury model of status epilepticus (Varvel et al., in
preparation). BP, HR, and BW were measured weekly for 5 weeks. On
D39, mice were injected intraperitoneally with 12 mg/kg of pilocarpine,
a muscarinic receptor agonist that has been shown to elevate blood
pressure and reduce heart rate [41-43], and BP and HR were measured
as a test of the sensitivity of the apparatus. On D41 mice were switched
to a high salt diet (HSD) for 14–19 days with their BP, HR and BW
measured weekly and at the end of study (Fig. 1A).
2.6. Determination of blood pressure and heart rate in mice (cohort 1)

2.8. Determination of respiratory function in rats (cohort 3)

Systolic blood pressure (SBP) and heart rate (HR) of mice were
measured using a tail-cuff method [44] with BP-2000 blood pressure
analysis system (Visitech Systems), which measures BP and HR by
transmission photoplethysmography. A total of n = 24 animals, 12
males and 12 females were used in the study; animals were randomized
into vehicle arm or TG11–77. HCl treatment arm (57 mg/kg/day), with
both groups consisting of 6 males and 6 females. On the day of mea
surement, mice were acclimatized to the procedure room for 30 min
before experiment. Then, 6 animals at a time were immobilized on the
heated platform (37 oC) using adapters specific to mice. The mouse tail
was put into tail-cuff and fixed using tape. Once immobilized, mice were
given 10 min to get accustomed to being restrained on the platform
before measurements were commenced. BP and HR were measured a
total of 20 times with each recording episode being 45 s, with 5 trial
readings followed by 15 experimental readings. For data to be consid
ered for final analysis, at least 10 out of 15 readings had to be recorded,
with a standard deviation of < 10%. If an animal’s readings did not meet
the criteria, it was rested for a minimum of 30 min and the measure
ments were redone. In case of pilocarpine injection, if an animal’s
readings did not meet the criteria it was excluded from final analysis, as
it was not possible to reinject them and redo the measurements. Out of
24 animals, 6 were excluded for BP and 5 were excluded for HR. Output
of the experiment was given by the software in the form of individual
readings and average reading for BP and HR.
Statistical analysis: Paired or unpaired t-test were used for analysis
depending on the requirement of the data set. GraphPad Prism was used
for analysis.

This study was performed by SRI biosciences following our in
structions. The objective of this study was to evaluate the acute respi
ratory effects of TG6–10–1 when given via intraperitoneal injection to
Sprague Dawley rats. Vehicle (10% DMSO, 50% PEG400, and 40% DI
water) or TG6–10–1 in the vehicle was administered as a single dose by
intraperitoneal injection to 4 groups (Groups 1 through 4) of 8 male
Sprague Dawley rats/group at 0, 5, 20, or 50 mg/kg, respectively
(n = 32). For measurement of respiratory function parameters, each rat
was placed in a single-chamber, head-out, neck-sealed plethysmograph.
Respiratory frequency, tidal volume, and calculated minute volume
were collected for at least 60 min prior to dosing and for at least 5 h
postdosing.
Statistical analysis: Analysis was performed for a period of 1 h post
injection (PI) and was compared to 0 mg/kg value for the corresponding
time point post injection. 2-way ANOVA with Tukey’s multiple com
parison test was performed for analyzing the data. GraphPad Prism was
used for analysis.
2.9. Determination of organ toxicity and brain-to-plasma ratio in mice
(cohort 4)
C57BL/6 male mice at 8 weeks of age (n = 24) were subjected to
either vehicle (i.e., drinking water at pH 3.5) or TG11–77. HCl (average
of 62 mg/kg/day) treatment through drinking water. After 4 weeks of
treatment, mice were perfused with ice cold PBS to harvest different
organs. Before perfusion, blood was collected by cardiac puncture and
stored in EDTA tubes for further processing to separate plasma. Heart,
liver, kidney, and spleen were collected, and wet weights immediately
measured. Brain tissues were dissected to separate into neocortex and
hippocampus before measuring their weights. All organ weights were
normalized to the body weights of the individual mice. For determina
tion of compound in brain and plasma, blood samples were collected in
microcentrifuge tubes containing K2EDTA as anticoagulant. Plasma was
separated by centrifugation of whole blood and stored below − 70 ºC
until analysis. Whole brain samples were homogenized using phosphate
buffered saline (pH 7.4) and the total homogenate volume was thrice the
brain weight. All samples were processed for analysis by protein pre
cipitation using acetonitrile (ACN) and analyzed by LC-MS/MS (lower
limit of quantification (LLOQ) was determined to be 1.23 ng/ml). Wa
ters Xterra MS C18 column was used with flow rate 0.8 ml/min using the
mobile phase 0.1% formic acid in acetonitrile (pump A) and 0.1% formic
acid in water (pump B). Internal standard glipizide (ret. time 1.60 min)
was used to quantify the peaks and the ratio was used for concentration

2.7. Determination of blood pressure, pulse pressure, heart rate and body
temperature in rats (cohort 2)
This study was performed by SRI Biosciences following our in
structions. The objective of this study was to measure the effects of IP
injection of TG6–10–1 on blood pressure (systolic, diastolic, and mean),
pulse pressure, heart rate, and body temperature in conscious Sprague
Dawley rats instrumented with a radiotelemetry transmitter. Pilocarpine
was again used as a positive control compound. A total of n = 24 ani
mals were randomized and used in this study. Pilocarpine (12 mg/kg)
and TG6–10–1 (50 mg/kg) in its vehicle (10% DMSO, 50% PEG400, and
40% DI water) were administered as a single dose by intraperitoneal
injection into male Sprague Dawley rats following maintenance at low
and high salt diets. Heart rate, arterial blood pressure (systolic, diastolic,
pulse, and mean arterial pressure), and body temperature were collected
every 2 min for at least 24 h prior to dietary change or treatment on
4
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analysis in the brain and plasma. The bioanalysis of the samples was
done at Sai-life (CRO company), India.
Statistical test: Unpaired t-test with Bonferroni correction was applied
between groups for different organ weights. GraphPad Prism was used
for analysis.

was then automatically progressed to the remaining slices. Bone volume
and density parameters were estimated from all mid-diaphyseal scans.
For both metaphyseal scans, all images were first run through an autocontouring script to delineate the boundary of the trabecular region
within the cortical shell. Subsequently, 100 slices starting at a fixed
number of slices distal to the end of the growth plate (and moving to
wards the mid-diaphysis, away from the knee joint) were analyzed after
further manual adjustments of the contours as needed to better define
the trabecular regions or margins. Total bone volume, density, and
trabecular network parameters were estimated for all samples (Supple
mentary Fig S2).
Statistical analysis: Unpaired t-test with Holm-Sidak correction for
multiple comparisons was applied between groups. p = 0.05 was
selected as the threshold for change. GraphPad Prism was used for
analysis.

2.10. Rotarod test (cohort 4)
Rotarod test trials were performed using the Rotamex rotarod (Co
lumbus Instruments) in an isolated room. The device was set in an
accelerating mode with initial speed at 4 rpm and increasing linearly to
40 rpm over 5 min. On the testing days, mice (n = 24) were transported
to the rotarod room two hours before the trials started. Either TG11–77.
HCl (62 mg/kg/day) or vehicle treated mice were placed on the moving
rod (1.5-inch diameter) separated by plexiglass sheets and the latency to
fall from the rod was recorded for each mouse using automated timers
set at the platform. Each day mice were subjected to 4 trials for 5 min
each and after each trial, they were housed in the resting cage for 20 min
before their next trial. If the mice did not fall at the end of the trial, their
latency to fall was measured as 300 s. Mice were tested on day 0, 7, 14,
21 and 28 and their average latency to fall over days was represented as
an index of muscle coordination upon drug treatment.
Statistical analysis: Two-way repeated measure ANOVA with Sidak’s
multiple comparisons test was applied for rotarod analysis. GraphPad
Prism was used for analysis.

2.13. Bone histology in C57BL/6 mice treated either with vehicle or TG11–77.HCl (cohort 6)
The bone samples from the bone phenotyping experiment were used
for this analysis. Tibia and femur samples were fixed in 10% neutralbuffered formalin and then stored in 70% ethanol until processed.
Samples were decalcified then processed for standard histology and
stained with hematoxylin and eosin. Histological sections were exam
ined under a light microscope (Olympus BX41) by a board-certified
veterinary pathologist. Representative images were prepared using a
digital camera (Olympus DP25) and a connected imaging software
(Olympus cellSens Standard). Samples were analyzed blindly. Cancel
lous bone density for each bone section was qualitatively scored on a
scale of 0–5 (0 = most depleted cancellous bone density and 5 = normal
density of cancellous bone).
Statistical analysis: Unpaired t-test with Holm-Sidak correction for
multiple comparisons was applied between groups. p = 0.05 was
selected as the threshold for change. GraphPad Prism was used for
analysis.

2.11. Determination of complete blood count in mice (cohort 5)
Samples of fresh arterial blood were analyzed for complete blood
count (CBC) in 20-week-old males and females (n = 56), treated with
vehicle (drinking water at pH 3.5) or TG11–77. HCl (58 mg/kg/day) in
drinking water for 12 weeks. CBC analysis was performed by the Quality
Assurance & Diagnostic Lab, Division of Animal Resources, Emory
University. Blood samples were collected into K2EDTA tubes, stored at
4 ◦ C and analyzed within 24 H by a VetScan HM5 v2.3 Hematology
Analyzer.
Statistical analysis: Multiple unpaired t-test with Bonferroni correc
tion for multiple comparisons was applied between groups. p = 0.05
was selected as the threshold for change. GraphPad Prism was used for
analysis.

3. Results
3.1. Chronic exposure to high dose EP2 antagonist did not significantly
alter body weight of mice
Compared to vehicle, mice treated with TG11–77. HCl (57 mg/kg/
day) showed lower % increase in body weight over the 5 weeks of
treatment (7.64% increase versus 10.7%, Fig. 1B). However, this
observed difference was not statistically significant (p = 0.11). In female
mice, the weight increase in vehicle versus TG11–77. HCl treated mice
was 9.83% versus 6.15% (p = 0.054), whereas in male mice vehicle
treated animals showed an increase of 11.6% versus 9.13% in TG11–77.
HCl treated mice (p = 0.73) (Fig. 1C). It is worth noting that mice on
vehicle treatment trended an increase of 0.8% after one week, whereas
TG11–77. HCl treated mice trended a decrease of 1.32% body weight
(Fig. 1D), but these observations are also statistically non-significant
(P > 0.05, two-way ANOVA).

2.12. Bone phenotyping analysis in mice by MicroCT (cohort 6)
C57BL/6 mice of both sexes at 10 weeks of age (n = 30) were
randomly subjected to either vehicle (drinking water with adjusted pH
2.8) or TG11–77. HCl (134 mg/kg/day) in vehicle. After 4 weeks of
treatment, mice were sacrificed by overdose of isoflurane and bones
were collected immediately from both hind limbs. Tibia and femur were
separated, and the muscles and ligaments were carefully removed using
a tweezer. They were then fixed in 4% paraformaldehyde solution in PBS
overnight and stored in 70% ethanol at 4◦ C till further analyzed.
Bone samples were shipped to the Microcomputed Tomography
(µCT) Core at Georgia Tech, Atlanta for bone phenotyping analysis.
Tibia and femur pairs were immersed vertically in specimen holders and
supported by foam pieces to maintain orientation. µCT scans of the long
bone mid-diaphysis and the metaphysis near the knee joint were per
formed using a Scanco CT40 (6 µm voxels, 300 ms). For the diaphyseal
scans, the length of the long bone was estimated from scout view images
and 158 slices (6 µm) straddling the approximate mid-point were ac
quired. For tibial metaphyseal scans, 368 slices starting at the proximal
end of the tibia were acquired to encompass the proximal metaphysis.
Similarly, for femoral metaphyseal scans, 525 slices including the distal
end of the femur were acquired to encompass the distal metaphysis.
Each mid-diaphyseal scan was manually contoured at the initial slice
around the outer margins of the cortex and then automatically adjusted
with the native software for best fit around the cortex. The contouring

3.2. Chronic TG11-77.HCl treatment did not alter mouse blood pressure
(BP) or heart rate (HR)
To determine the effect on cardiovascular system, we used a tail-cuff
method on mice to measure the systolic blood pressure (SBP) and HR
every week. After five weeks of treatment with TG11–77. HCl (57 mg/
kg/day), there was no significant difference in the blood pressure of
vehicle treated mice versus TG11–77. HCl treated mice (Fig. 1E).
Furthermore, no significant difference was observed in BP of mice
treated with either vehicle or TG11–77. HCl, on any given week during
the treatment (Supplementary Fig. S1A).
Similarly, mice treated with TG11–77. HCl for 5 weeks showed no
5
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significant difference in HR compared to vehicle treated mice (Fig. 1F).
There was a significant increase in heart rate of mice after one week of
treatment, but this increase in heart rate was similar in cohort treated
with TG11–77. HCl and vehicle, suggesting the increase in heart rate
might be a vehicle (pH 3.5 water) effect (Supplementary Fig. S1B).
To test the effectiveness of our experimental procedure in measuring
changes in BP and HR we used pilocarpine (12 mg/kg) as a positive
control. Mice showed a significant increase in BP (95.2 mm Hg versus
105 mm Hg, p < 0.05) (Fig. 2A) within 30 min of pilocarpine injection.
Treatment with pilocarpine resulted in significant reduction of HR (724
bpm versus 419 bpm, p < 0.0001) (Fig. 2C). However, in mice treated
with vehicle versus EP2 antagonist TG11–77. HCl, there was no signif
icant difference in the pilocarpine-induced change in BP (Fig. 2B) and
HR (Fig. 2D). These results together indicate that EP2 antagonist
TG11–77. HCl does not alter the cardiac response of mice, either under
basal conditions or after pilocarpine.

3.5. Chronic TG11-77.HCl administration does not affect cellular
composition and characteristics of blood in mice

3.3. TG11-77.HCl did not alter blood pressure and heart rate of mice on
high sodium (salt) diet (HSD)

The above results indicate that chronic treatment of mice with the
EP2 antagonist produced no effects on BP and HR. To generalize this
conclusion we investigated a second EP2 antagonist, TG6–10–1, which
displayed anti-inflammatory and neuroprotective efficacy in multiple
models of brain injuries [6,8,24,45-49]. Here we utilized rats (n = 12) as
animal species and used acute high dose administration of TG6–10–1 to
study the effect on cardiovascular function. We studied the effects of
TG6–10–1 on blood pressure (systolic, diastolic, and mean), pulse
pressure, heart rate, and body temperature in conscious Sprague Dawley
rats instrumented with a radiotelemetry transmitter.
Acute administration by single intraperitoneal injection of TG6–10–1
at 50 mg/kg showed no significant change in cardiovascular function
parameters of rats including heart rate (HR) (Fig. 5A), systolic blood
pressure (SBP) (Fig. 5B), diastolic blood pressure (DBP) (Fig. 5C), mean
arterial pressure (MAP) (Fig. 5D), pulse pressure (PP) (Fig. 5E) as well as
body temperature (BT) (Fig. 5F). This dose is 5-fold higher than the
efficacious dose [8,9]. Moreover, when animals after 7 days of high
sodium diet (HSD) were injected with TG6–10–1, it had no effect on any
of the cardiovascular parameters measured (Fig. 5). As expected, the
positive control pilocarpine (12 mg/kg, IP injection) significantly
decreased HR and BT (Fig. 5A and F), significantly increased SBP
(Fig. 5B), DBP (Fig. 5C), MAP (Fig. 5D) and PP (Fig. 5E) in rats irre
spective of their diet.

To determine whether chronic administration of TG11–77. HCl
altered the cellular composition of blood in mice, we investigated a
separate cohort of mice (cohort 3, n = 56) after treatment with
TG11–77. HCl. Interestingly, TG11–77. HCl treatment (58 mg/kg/day)
for 12 weeks did not produce any significant changes in complete blood
counts, namely, red blood cells (RBCs), lymphocytes, monocytes, neu
trophils and platelets (Fig. 4A), although monocyte counts trended
lower. Similarly, hemoglobin, hematocrit levels, red cell distribution
width (RDWc) and platelet cell distribution width (PWDs) were unal
tered (Fig. 4B). These observations suggest that chronic dosing of EP2
antagonist has no adverse effect on cellular composition of blood.
3.6. Acute administration of EP2 antagonist, TG6-10–1, did not alter
cardiovascular function in rats

As shown in Fig. 1A, we used the same cohort of mice, but switched
them from regular diet to high-salt diet on day 41 and continued until
Day 55–59 on high-salt diet with vehicle or EP2 antagonist treatment.
Mice treated with a diet containing 10-fold elevated sodium showed a
significant increase in their systolic blood pressure (SBP) after 14–19
days, compared to pre-HSD systolic blood pressure (109 mmHg versus
102 mmHg, p < 0.01) (Fig. 2E). When analyzed separately, this differ
ence in systolic blood pressure observed in males was not statistically
significant (113 mmHg versus 109 mmHg, p = 0.25) (Fig. 2F), but in
females, HSD resulted in significant increase in systolic blood pressure
(105 mmHg versus 96.1 mmHg, p < 0.05) (Fig. 2G). However,
TG11–77. HCl (57 mg/kg/day) did not alter the effect of a high salt diet
on systolic blood pressure (Fig. 2H).
There was a significant elevation in HR of mice post-HSD versus preHSD (735 bpm versus 684 bpm, p < 0.0001) (Fig. 2I). This increase in
post HSD HR was independent of sex with significant changes observed
in both male (741 bpm versus 708 bpm, p < 0.05) (Fig. 2J) and female
(729 bpm versus 662 bpm, p = 0.0001) (Fig. 2K). However, change in
HR of mice treated with vehicle versus TG11–77. HCl, pre- versus postHSD was not significantly different (ΔHR post versus pre-HSD 55.9 bpm
versus 45.3 bpm, p = 0.54) (Fig. 2L). These data indicate that the car
diac effects of the global EP2 KO [30,31] are not replicated by chronic
exposure of adult mice to an EP2 antagonist.

3.7. Acute TG6-10–1 administration did not modify respiratory function
in healthy rats
To study the effect of EP2 antagonist on respiratory function, respi
ratory assessment was performed following single intraperitoneal in
jection of TG6–10–1 in plethysmograph-restrained Sprague Dawley rats
(separate cohort, n = 32) that were treated with vehicle and three
different doses of TG6–10–1. There was no significant effect observed on
respiratory function of rats determined by breaths per minute after
single injection of TG6–10–1 at the doses 5 mg/kg, 20 mg/kg, and
50 mg/kg when compared to vehicle injected rats (see methods for de
tails). All three parameters of respiratory function, respiratory frequency
(Fig. 6A), tidal volume (Fig. 6B), and minute volume (Fig. 6C) showed
similar values in 15-minute intervals at different doses of TG6–10–1 for
up to 60 min after injection (Fig. 6).

3.4. TG11-77.HCl had no adverse effect on motor behavior and vital
organ weight in mice
A separate cohort of mice (cohort 2, n = 24) was used to ask whether
chronic administration of this EP2 antagonist adversely affects overall
health, and to determine if therapeutic drug levels are found in the
plasma and the brain. In this study, treatment with TG11–77. HCl
(62 mg/kg/day) for 4 weeks did not have significant effect on body
weight (Fig. 3A) or motor performance of mice when compared to
vehicle as determined by the rotarod test by measuring latency to fall
(Fig. 3B). Similarly, 4 weeks of TG11–77. HCl treatment did not change
the weight of internal organs such as heart, spleen, kidney, and liver
along with no differences observed in weight of brain tissues cerebral
cortex, hippocampus, and striatum (Fig. 3C), indicating no overt toxicity
by chronic treatment with the EP2 antagonist. We analyzed the con
centration of TG11–77. HCl in plasma and brain of the mice used in this
study and found about 3-fold higher total concentration of the TG11–77
in plasma, and 4.5-fold higher in the brain than its Schild potency
against EP2 receptor (Schild KB = 9.7 nM) [39] with brain-to-plasma
ratio of 1.4. (Fig. 3D).

3.8. Chronic treatment with EP2 antagonist TG11-77.HCl does not affect
bone volume and bone density in naïve mice, but results in slight reduction
in trabecular number only in male mice
Given the beneficial effect of an EP2 agonist in a model of boneinjury [32,33], we asked whether pharmacological antagonism of EP2
has any detrimental impact on bone volume and density in healthy mice.
We used a separate cohort of mice (cohort 4, n = 30) and tested the
6
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Fig. 2. EP2 antagonist TG11–77.HCl, had no significant effect on mice systolic blood pressure (SBP) and heart rate (HR) on regular diet and high-salt diet. Effect of
pilocarpine (pilo) injection (12 mg/kg) on blood pressure (BP) (A) of mice on D39 compared to pre-pilo (D35). Pilocarpine treatment resulted in elevated BP of mice
vs pre-pilo levels (104 mmHg vs 95.2 mmHg, p < 0.05, paired t-test). Pilocarpine treatment resulted in significant reduction in heart rate (HR) (C) of mice, when
compared to pre-pilo levels (419 bpm vs 724 bpm, p < 0.0001, paired t-test). Change in BP and HR of mice in vehicle vs TG11–77.HCl group did not differ
significantly upon treatment with pilocarpine. Change in BP was 7.3 mmHg in vehicle group vs 10.8 mmHg in TG11–77.HCl group (p = 0.69, unpaired t-test with
Welch’s correction, with an anticipation of unequal variance) (B). In case of HR, in vehicle group the change after pilo was 315 vs 287 in TG11–77.HCl group
(p = 0.32, unpaired t-test with Welch’s correction) (D). Effect of high salt diet (HSD) on BP and HR of mice. After switching to HSD, there was a significant increase in
BP of mice compared to pre-HSD levels (108 mmHg vs 102 mmHg, p < 0.01, paired t-test) (E). This effect of HSD on systolic blood pressure was observed both in
male (112 mmHg vs 109 mmHg, p = 0.25, paired t-test) (F) and female (105 mmHg vs 96.1 mmHg, p < 0.05, paired t-test) (G) mice pre- and post-HSD. Effect of
TG11–77.HCl on HSD induced BP change. There was no significant effect observed in change of systolic BP pre- and post-HSD in mice treated with vehicle vs
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TG11–77.HCl (ΔBP (post vs pre-HSD) 5.05 mmHg vs 7.79 mmHg, p = 0.56 respectively, unpaired t-test with Welch’s correction) (H). There was a significant elevation in
HR of mice pre-HSD vs post-HSD (684 bpm vs 734 bpm, p < 0.0001, paired t-test) (I). This increase in post HSD HR was independent of sex of mice with significant
changes observed in both male (708 bpm vs 741 bpm, p < 0.05, paired t-test) (J) and female (662 bpm vs 728 bpm mice, p = 0.0001, paired t-test) (K). Change in HR
of mice treated with vehicle vs TG11–77.HCl, pre vs post HSD was not significantly different (ΔHR post vs pre-HSD 45.3 bpm vs 55.9 bpm, p = 0.54 respectively,
unpaired t-test) (L). These observations show that TG11–77.HCl does not alter changes in BP and HR induced by HSD. p < 0.05 was considered significant. The data
are reported as mean ± SD.
Fig. 3. EP2 antagonist TG11–77.HCL (62 mg/
kg/day for 4 weeks), had no adverse effect on
motor behavior and organ composition:. (A)
Body weight of mice treated with TG11–77.HCl
did not differ from mice treated with vehicle.
(B) Performance on Rotarod (% of total 300 s
time spent on before fall) test shows no differ
ence at any time point. (C) weight changes to
vital organs- liver, heart, spleen, kidney and
brain tissues also show no difference. Organ
and brain region weights are normalized to
body weight. Two-way repeated measure
ANOVA with Sidak’s multiple comparisons test
was applied for Rotarod and body weight
analysis. Unpaired t-test with Bonferroni
correction was applied between groups for
different organ weights. P values were set to be
significant at * <0.05(D) Chronic oral dosing of
TG11–77.HCl in drinking water achieves 3-fold
more concentration in plasma and 4.5-fold
more in brain than the Schild potency (KB) of
the molecule which is 9.7 nM [39], with a
brain-to- plasma ratio 1.4. The data with
± SEM. N = 24 mice were used in this study.

effect of chronic TG11–77. HCl treatment on bone phenotype. Both male
and female C57BL/6 mice were treated with vehicle or TG11–77. HCl
(134 mg/kg /day) in drinking water for 4 weeks. The tibia and femur
from hind limbs were subjected to Microcomputed Tomography (µCT)
scan to analyze the bone mass through diaphyseal scan and trabecular
network through metaphyseal scan (Supplementary Fig. S2). The
diaphysis of 0.6 mm volume-of-interest (VOI) at the mid shaft of tibia
and femur did not show any difference in bone volume and density
between TG11–77. HCl and vehicle treated mice in both males
(Fig. 7A-C) and females (Fig. 7D-F). The TG11–77. HCl treatment also
did not show any difference in the bone volume and density in meta
physeal scan at the growth plates of tibia and femur in both sexes,
revealing there was no adverse effect of the TG11–77. HCl treatment in
these mice (Fig. 7A-F). Interestingly, the metaphyseal scan of the
trabecular network showed a significant decrease in trabecular numbers

upon TG11–77. HCl treatment only in males without altering the
trabecular thickness and spacing (Supplementary Fig. S3). In contrast to
the males, the trabecular numbers in females were found to be moder
ately increased but, as in males, no changes were observed in trabecular
thickness and spacing (Supplementary Fig. S3). To evaluate further the
effect of TG11–77HCl on trabecular network, in particular in trabecular
number in male mice, we sectioned the fixed and decalcified samples of
tibia and femur and analyzed by histology using H&E staining. We found
no difference in cancellous bone density between the groups treated
with vehicle or EP2 antagonist (supplementary Fig. S4). This result is
discordant with the finding from microCT (Fig. S3 A-B). Overall, we
conclude that treatment with the EP2 antagonist at high dose for up to 1
month is unlikely to have a detrimental effect on bone density of healthy
animals.
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Fig. 4. Chronic treatment with EP2 antagonist
TG11–77.HCl (58.1 mg/kg/day for 12 weeks),
did not have an effect on blood cell counts in
mice: (A) No differences were found in RBCs,
Platelets and different population of WBCs after
12 weeks of oral dosing with TG11–77.HCl
compared to vehicle, suggesting no peripheral
effects of the drug in blood. (B) TG11–77.HCl
treatment did not have any adverse effect on
the level of hemoglobin (HGB), hematocrit
(HCT) and cell distribution width of RBC and
platelets in these mice. Data was statistically
analyzed in GraphPad Prism. Multiple unpaired
t-Test with Bonferroni correction was applied
between groups. The data are with ± SD.

4. Discussion

to have a better understanding of the effects of EP2 antagonism on
respiratory and cardiovascular functions.
EP2 receptor activation is associated with acute and chronic
inflammation and autoimmune diseases [2]. EP2 receptor’s involvement
in inflammation and immune response is well established in both
in-vitro [51-54] and in-vivo models [17,51]. Therefore, we intended to
determine whether chronic treatment EP2 would induce any immuno
genic responses in the blood. Our study showed no difference in blood
composition of healthy mice treated with either vehicle or EP2 antag
onist, TG11–77. HCl (Fig. 4). This observation further enhances the
chance of pharmacological inhibition of EP2 to be a viable therapeutic
target.
An EP2 agonist, when directly injected into the bone marrow,
induced bone healing in canine model of bone fracture [32], and
administration of PGE2 (agonist, via EP2) prevented degeneration of
articular cartilage during the early stages of osteoarthritis in rabbits
[33], suggesting EP2 activation can play a role in bone repair and
healing. On the other hand, activation of EP4 receptor, but not EP2,
rescued the impaired bone healing [55], and EP2 deletion in mouse
cultures impairs osteoclastogenesis [56], suggesting EP2 antagonism
might be beneficial. Considering these mixed results, we tested an EP2
antagonist for adverse effects on bone phenotype. A high dose of EP2
antagonist TG11–77. HCl (134 mg/kg/day freebase) in drinking water
for 28 days did not have any effect except number of bone trabeculae in
the marrow cavity in males that was significantly reduced in the treated
group. This observation can be explained by the role of prostaglandins in
bone resorption and formation. It has been shown that systemic injec
tion of prostaglandins can increase bone resorption and formation, but
bone formation usually exceeds resorption; therefore, prostaglandin
receptor antagonists can induce bone resorption [57]. Furthermore,
prostaglandin treatment results in increased bone mass in male rats.
Therefore, EP2 receptor antagonists could cause bone loss in male rats
[58]. This observation must be further investigated to understand the
interplay between sex hormones and TG11–77. HCl. A limitation of our
study is that we did not investigate EP2 antagonist efficacy in a
fractured-bone model. Therefore, our results further warrant explora
tion of EP2 antagonist efficacy in rheumatological models such as
osteoarthritis and rheumatoid arthritis, or injured bone-models to un
derstand whether EP2 receptor signaling will promote the activity of
cells that are involved in bone remodeling process.

In spite of the breadth of preclinical data suggesting the value of EP2
antagonists [50], there are limited advances towards clinical develop
ment. This is in part due to two published results that indicated EP2
global deletion reduces reproductive capability and arterial blood
pressure and induces salt-sensitive hypertension [30,31]. Therefore,
exacerbating salt-sensitive hypertension would effectively preclude the
chronic use of EP2 antagonists in humans. However, these studies could
not distinguish between pharmacologically (acute or chronic) dimin
ished EP2 activation and a developmental defect in these mice. Other
studies reported that EP2 agonists promote healing of bone fractures
[32], raising further doubts about potential adverse effects of EP2 an
tagonists. In brief we found no effects of high dose pharmacologic EP2
block on cardiovascular or respiratory parameters, bone structure or
blood cell counts.
We tested two EP2 antagonists in adult EP2-expressing rodents: one
antagonist (TG11–77. HCl) by chronic oral administration in mice, and
another (TG6–10–1) by acute injection into rats. It is worth emphasizing
that the cardiovascular and fertility adverse effects were only reported
in EP2 global KO mice, and beneficial effects were reported in normal
mice with the use of EP2 agonist. We wanted to monitor potential
adverse effects in more than one rodent species (mouse and rat), using
more than one EP2 antagonist, and by chronic and acute dosing pro
tocols so the results can be generalized.
Chronic treatment with an EP2 antagonist showed no adverse effect
on cardiovascular function in mice (Figs. 1, 2). Moreover, acute
administration of an EP2 antagonist at high dose in rats was without any
effect on cardiovascular (Fig. 5). These results are in discord with earlier
findings, which indicated that EP2 gene KO results in reduced systolic
blood pressure in mice on regular diet in one study [30], increased
baseline systolic blood pressure in mice with high-salt diet in another
study [31]. The discordance between our findings and previous reports
using EP2 gene KO animals may be attributed to role of EP2 in devel
opment at prenatal and postnatal stage, which further complicates the
co-morbidities such as cardiovascular, respiratory function and fertility
efficacy. Our experimental results show that acute IP administration of
an EP2 antagonist does not have any adverse effect on normal respira
tory function in rats (Fig. 6). However, our study is limited to use of
healthy mice and rats, therefore, further research in animals with un
derlying respiratory disease, such as asthma, would be a logical next step

9

V. Rawat et al.

Biomedicine & Pharmacotherapy 147 (2022) 112646

Fig. 5. Acute administration of EP2 antagonist
TG6–10–1 (50 mg/kg), in rats does not effect
the cardiovascular function. Male SD-Rats on
either Regular Diet (RD) or High Salt Diet
(HSD) were injected with TG6–10–1 (50 mg/
kg) and their cardiovascular function was
monitored for 2 h. Compared to baseline levels
(BL) there was no significant effect of
TG6–10–1 on Heart Rate (HR) (A), Systolic
Blood Pressure (SBP) (B), Diastolic Blood
Pressure (DBP) (C), Mean Arterial Pressure
(MAP) (D), Pulse Pressure (PP) (E) and Body
Temperature (BT) (F) of animals. Whereas
pilocarpine, the positive control in the experi
ment, resulted in significant changes SBP,
DBP, MAP, PP and BT of animals on LSD and
HR, SBP, DBP, MAP, PP and BT of animals on
HSD. Statistical analysis was done using 3way ANOVA with Tukey’s multiple compari
son, p < 0.05 was considered significant.
* =p < 0.05, * *=p < 0.01, * ** =p < 0.001,
* ** *=p < 0.0001. The data are with ± SD.

5. Conclusion

indication. In this study, we provide experimental evidence that use of a
small molecule EP2 antagonist by acute and chronic delivery should be
safe for cardiovascular, respiratory, basic immune response, and bone
density in healthy animals. Our results alleviate long-held reservations,
which were merely derived from the studies of EP2-global knockout
animals, against targeting EP2 and paving a path for EP2 antagonist to
use against array of diseases. Further studies with EP2 antagonist in
disease specific models are required to promote EP2 antagonist as a
clinical agent.

A number of inflammatory CNS and peripheral diseases are exacer
bated by excessive PGE2 induction and its actions in particular via
activation of EP2 receptor. Therefore, EP2 receptor antagonism with a
small molecule has a therapeutic value. However, PGE2 and EP2 are also
had a physiological role in relaxing the vascular, respiratory and other
smooth muscles, therefore, de-risking experiments with small molecules
targeting physiological EP2 actions in naïve animals were necessary to
advance a small molecule antagonist for clinical use for any disease
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Fig. 6. Acute administration of EP2 antagonist (TG6–10–1) has no effect on respiratory function in normal male rats. Respiratory Frequency (RF) (A), Tidal volume
(TV) (B) and Minute volume (MV) (C). Animals injected with either vehicle (0 mg/kg) or TG6–10–1 at 5 mg/kg, 20 mg/kg and 50 mg/kg were monitored for
respiratory parameters. TG6–10–1 did not have any significant effect on RF, TV or MV when compared to animals injected with vehicle, baseline (BL) values were
compared to different time points post treatment (PT). Statistical analysis was done using 2-way ANOVA with Tukey’s multiple comparison, p < 0.05 was considered
significant. The data are with ± SD.

Fig. 7. Treatment of mice with EP2 antagonist (TG11–77.HCl at 134 mg/kg/day for 4 weeks) had no adverse effect on bone mass of tibia and femur in C57BL/6
mice. 0.6 mm VOI diaphyseal scan of tibia and femur at mid shaft in male (A) and female mice (D). Quantification of bone volume and bone density between vehicle
and TG11–77.HCl treatment showed no difference in male (B-C) or female (E-F) tibia and femur at diaphysis and metaphysis. Unpaired t test with Holm-Sidak
correction for multiple comparisons was applied between group (α = 0.05). The data are with ± SEM.
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